Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Anniston

Birmingham

Gulf Shores

Huntsville

Mobile

Muscle Shoals

Chandler

Glendale

Goodyear

Tucson

Harrisburg

Little Rock

Searcy

Chula Vista

Concord

Escondido

Hawaiian Gardens

La Mesa

Los Angeles

Oceanside

San Jose

Santa Rosa

Walnut Creek

Colorado Springs

Denver

Stamford

Brandenton

Brooksville

Fort Lauderdale

Hialeah

Jacksonville

Miami

New Port Richey

Oviedo

St. Petersburg

Tampa

Decatur

Marietta

Roswell

Savannah

Boise

Arlington Heights

Chicago

Evansville

Indianapolis

Council Bluffs

Augusta

Newton

Overland Park

Wichita

New Orleans

Oxon Hill

Ypsilanti

Saint Paul

St Louis

Fremont

Omaha

Las Vegas

Berlin

New Windsor

Rochester

Charlotte

Durham

Hickory

Morehead City

Raleigh

Wilmington

Winston-Salem

Cincinnati

Cleveland

Delaware

Kettering

Lyndhurst

Wadsworth

Willoughby Hills

Oklahoma City

Tulsa

Eugene

Greer

Spartanburg

Austin

Corpus Christi

Dallas

Houston

Hurst

Katy

Magna

West Jordan

Burke

Richmond

Virginia Beach

Renton

Kenosha